Skip to content
Screener

Protagonist Therapeutics PTGX Q1 2025 earnings

Reported May 6, 2025 · Before market open

Revenue$28.3MBeat by $21.8M
EPS-$0.19Beat by $0.31
Revenue estimate$6.6M
EPS estimate-$0.50

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$240.1M
EPS estimate$2.43

Financials

Q1 2025

Income statement

See full
Revenue$28.3M-88.9%
Operating income-$19.3M-109%
Net income-$11.7M-106%
EPS (diluted)-$0.19-106%

Balance sheet

See full
Cash & equivalents$139.7M-19.1%
Total debt$11.4M+2,359%
Total equity$689.1M+22.9%
Total assets$742.1M+17.9%

Cash flow

See full
Operating cash flow$125.4M+557%
CapEx$545.0K+125%
Free cash flow$124.8M+551%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$2.97B+68.6%
Enterprise value$2.84B+78.8%
P/E52.8×—
P/S14.3×+8.7×

Profitability

See full
Operating margin13.1%—
Net margin27%—

Returns & leverage

See full
Return on equity9%—
Debt / equity0×0.0×
Current ratio17.3×+1.5×

FAQ

When did Protagonist Therapeutics report Q1 2025 earnings?
Protagonist Therapeutics (PTGX) reported Q1 2025 earnings on May 6, 2025 before market open.
What were Protagonist Therapeutics's Q1 2025 revenue and EPS?
Protagonist Therapeutics reported revenue of $28.3M and eps of $-0.19 for Q1 2025.
Did Protagonist Therapeutics beat estimates in Q1 2025?
Revenue beat the consensus estimate of $6.6M by $21.8M. EPS beat the consensus estimate of $-0.50 by $0.31.
How did Protagonist Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 88.9% from $255.0M a year earlier.
Where can I find Protagonist Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-045073) and the 10-Q periodic report (0001558370-25-006530) directly on SEC EDGAR. The filing index links above go to sec.gov.